Retrospective review of the antiemetic activity and anti-mental disorder of olanzapine in Soft- tissue sarcoma and Osteosarcoma patients with high-dose chemotherapy

Author:

Yin Jun-Yi1,Lv Xiao-Bin2,Zhou Yan1,Hu Hai-Yan1,Wang Qiong1

Affiliation:

1. Jiao Tong University Affiliated Sixth People's Hospital

2. Central Laboratory of the First Hospital of Nanchang

Abstract

Abstract Purpose: The aim of the study was to evaluate the role of olanzapine, which is an atypical antipsychotic drug, in antiemetic activity and anti-depression in soft-tissue sarcoma and osteosarcoma patients receiving high-dose chemotherapy. Methods: The retrospective observational study was performed at Shanghai Jiao Tong University Affiliated Sixth People's Hospital between 2017.1–2020.5 to observe the efficacy and safety of olanzapine combined with aprepitant,5-HT3 receptor antagonists and dexamethasone. We retrospectively reviewed the clinical records of soft-tissue sarcoma and osteosarcoma patients received highly emetogenic chemotherapy regimen, which containing cisplatin (75-100 mg/m2), doxorubicin regimen(60-75mg/ m2) or high-dose ifosfamide(8-12g/ m2). All included patients were more than 18 years old, with no history of drinking.140 patients were included in this study. These patients were assigned into two groups for olanzapine-containing therapy and non-olanzapine dual therapy. All patients received aprepitant,5-HT3 receptor antagonists and dexamethasone and in olanzapine group olanzapine was administered orally at 5mg/d from day1 to day 5. The study outcomes were complete response (CR), mental state evaluated by SAS and SDS, and quality of life (QoL) by the functional living index-emesis (FLIE) questionnaire. Results: The complete response (CR) rate in the olanzapine group was significantly higher than in the control group in delayed and overall phase (74.3% vs 47.1%, p=0.002; 67.1% vs 44.3%,p=0.010). No significant difference CR in acute phase was observed between the two groups. Meanwhile, the mental disorder including anxiety and depression in olanzapine group was ameliorated significantly (P<0.05). The patients in olanzapine group exhibited higher FLIE scores, which demonstrated better quality of life. More patients in the olanzapine group exhibited somnolence, constipation and fatigue. Conclusions: Olanzapine is safe and effective in preventing high-dose chemotherapy-induced nausea and vomiting and decreasing anxiety and depression in soft-tissue sarcoma and osteosarcoma patients. Meanwhile, patients in olanzapine group exhibit better QoL compared to non-olanzapine group. Further randomized studies are required to confirm these results.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3